US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

17.74

-0.0600-0.34%

Post-market: 17.800.0600+0.34%19:30 EDT

Volume:28.78K

Turnover:509.79K

Market Cap:104.67M

PE:- -

High:17.93

Open:17.89

Low:17.60

Close:17.80

52wk High:21.50

52wk Low:14.38

Shares:5.90M

Float Shares:5.90M

Volume Ratio:0.55

T/O Rate:0.49%

Dividend:0.71

Dividend Rate:4.03%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

HK Stock Market Update | Innovative Drug Stocks Face Continued Pullback Amid Shifting Overseas Rate Expectations and Post-2026 Negotiation Uncertainty

Wuxi Biologics (Cayman) Stock Slips 2.7% in Hong Kong

CSPC Pharmaceutical Group Stock Slips 3.6% in Hong Kong, Underperforms Competitors

Global Equities Roundup: Market Talk

Hong Kong Market Flash | CSPC Pharma Drops Over 4% as Lp(a) HORIZON Study Setback May Pressure Participants Including the Company

CSPC Pharma's Clinical Data Presentations Could be Near-Term Share Catalysts

WuXi Biologics Files HKEX Next-Day Disclosure, Share Capital Rises by 1.2 Million Shares

Transcenta Licenses HiCB Bioprocessing Technology to WuXi Biologics for RMB 10 Million Upfront

Transcenta Holding - to Receive RMB 10 Mln Upfront Payment and Milestone Payments

THOMSON REUTERS

Transcenta Holding - Grants WuXi Biologics Non-Exclusive License to Hicb Platform and Excelpro Cell Culture Media

THOMSON REUTERS

CSPC Pharma Gets Clinical Trial Nod in China for Solid Tumors Drug

MT Newswires Live

CSPC Pharmaceutical Says Rotigotine Long-Acting Injection Gets Clinical Trial Approval in China

CSPC Pharma's Goserelin Extended-Release Injection Gets Clinical Trial Green Light in China

CSPC Pharma Gains Chinese Clinical Trial Approval for Goserelin Extended-Release Injection

CSPC Pharma Wins China Clinical Trial Clearance for Syh9102 Goserelin Injection

CSPC Pharmaceutical - Goserelin Sustained-Release Injection (Syh9102 Injection) Obtains Clinical Trial Approval in China

THOMSON REUTERS

CLSA Highlights Return of Stock-Specific Drivers in China's Innovative Drug Sector, Sees Macro Swings as Entry Points

CSPC Pharmaceutical Gets China Approval for Eye Drug Clinical Trials

MT Newswires Live

CSPC Wins China Clinical Trial Approval for Syh2083 Dry Eye Drops

CSPC Pharmaceutical - Syh2083 Eye Drops Obtain Clinical Trial Approval in China

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/KURE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":17.74,"timestamp":1789156800000,"preClose":17.8,"halted":0,"volume":28778,"hourTrading":{"tag":"盘后","latestPrice":17.8,"preClose":17.74,"latestTime":"19:30 EDT","volume":110,"amount":1957.48,"timestamp":1789169406504,"change":0.06,"changeRate":0.003382,"amplitude":0.003382},"delay":0,"changeRate":-0.00337078651685406,"floatShares":5900168,"shares":5900168,"eps":0,"marketStatus":"Market Closed","change":-0.06,"latestTime":"09-11 16:00:00 EDT","open":17.89,"high":17.93,"low":17.6,"amount":509789.147232,"amplitude":0.018539,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":17.8,"sharesOutstanding":4750002,"nav":17.98,"aum":106101372.73,"dividendRate":0.040293,"bidAskSpread":0.008302,"postHourTrading":{"tag":"盘后","latestPrice":17.8,"preClose":17.74,"latestTime":"19:30 EDT","volume":110,"amount":1957.48,"timestamp":1789169406504,"change":0.06,"changeRate":0.003382,"amplitude":0.003382},"volumeRatio":0.5515710695008692,"impliedVol":0.3113,"impliedVolPercentile":0.6295},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5900168,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5515710695008692,"shares":5900168,"dividePrice":0.7148,"high":17.93,"amplitude":0.018539,"preClose":17.8,"low":17.6,"week52Low":14.3797,"pbRate":"--","week52High":21.5,"institutionHeld":0,"latestPrice":17.74,"eps":0,"divideRate":0.040293,"volume":28778,"delay":0,"ttmEps":0,"open":17.89,"prevYearClose":17.04,"prevWeekClose":18.9,"prevMonthClose":18.54,"prevQuarterClose":15.747,"fiveDayClose":18.91,"twentyDayClose":18.66,"sixtyDayClose":14.875},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1115866351","title":"HK Stock Market Update | Innovative Drug Stocks Face Continued Pullback Amid Shifting Overseas Rate Expectations and Post-2026 Negotiation Uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=1115866351","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115866351?lang=en_us&edition=fundamental","pubTime":"2026-09-11 11:13","pubTimestamp":1789096425,"startTime":"0","endTime":"0","summary":"Innovative drug concept stocks are experiencing sustained downward pressure in Hong Kong trading. As of the latest update, LEPU BIO (02157) has declined 3.91% to HK$38.05, while REMEGEN (09995) fell...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008369823.USD","MCRO","BK1574","LU0067412154.USD","LU2039709279.SGD","LU1226287792.SGD","BK1589","HK0000165453.HKD","LU1226287875.USD","IE00B5MMRT66.SGD","IE00B031HY20.USD","01093","LU0455707207.USD","LU0607220059.USD","BK4588","LU0502904849.HKD","LU1226288253.USD","BK1583","LU1188198961.HKD","LU1831875114.USD","IE00B543WZ88.USD","LU0140636845.USD","LU1226288170.HKD","LU1993786604.SGD","LU1152091168.USD","LU2242644610.SGD","LU0880133367.SGD","SG9999004220.SGD","KCAI","LU1960683339.HKD","LU0501845795.SGD","BK1191","LU0072913022.USD","WRTH","LU2488822045.USD","IE00BZ08YT58.USD","LU2097828714.EUR","LU1813983027.USD","VXUS","LU2097828631.EUR","LNGR","01801","LU2097828474.EUR","BK4585","LU0463099449.HKD","LU0244354667.USD","LU0326950275.SGD","LU1226287529.USD","LU1152091754.HKD","IE00BZ08YR35.GBP","IBBQ","LU1328277881.USD","LU1951186391.HKD","MEDX","LU0314109678.HKD","PEVC","09995","LU2097828805.USD","LU0149534421.HKD","BK1515","LU1969619763.USD","159992","KURE","LU2097828557.USD","IE0008368742.USD","LU0315179316.USD","LU1807302812.USD","LU2328871848.SGD","06978","LU1008478684.HKD","BK1161","IE00BZ08YS42.EUR","02157","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666195566","title":"Wuxi Biologics (Cayman) Stock Slips 2.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2666195566","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666195566?lang=en_us&edition=fundamental","pubTime":"2026-09-10 16:32","pubTimestamp":1789029120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. slipped 2.7% to 47.50 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.3% to 24954.47.This was the stock's second consecutive day of losses.Wuxi Biologics  Inc. closed 13% below its 52-week high of HK$54.45, which the company reached Aug. 26.Trading volume totaled 24.2 million shares, compared to the 50-day average of 37.8 million shares.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0043850808.USD","KURE","LU0307460666.USD","LU0856984785.SGD","BK1521","LU0456846285.SGD","LU3063872942.SGD","LU0320764599.SGD","LU0326950275.SGD","LU0359202008.SGD","IE00B0JY6N72.USD","LU1794554557.SGD","LU0572944931.SGD","LU0516423174.USD","LU0327786744.USD","LU0039217434.USD","LU0516422952.EUR","LU0128526141.USD","LU0588546209.SGD","SG9999002562.SGD","LU0456827905.SGD","LU1242518857.USD","LU0051755006.USD","LU0140636845.USD","LU0052750758.USD","LU1880383366.USD","LU0516423091.SGD","LU0819121731.USD","LU0516422440.USD","LU0823426480.USD","LU1688375341.USD","BK1589","BK1576","LU0029874061.USD","LU0348735423.USD","LU1242518931.SGD","LU0823426308.USD","BK1141","LU0348825331.USD","LU0708995583.HKD","LU0417516738.SGD","BK1610","LU0979878070.USD","02269","LU0516422366.SGD","LU1720050803.USD","LU0359201612.USD","LU2039709279.SGD","LU0417516902.SGD","SG9999002463.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666566165","title":"CSPC Pharmaceutical Group Stock Slips 3.6% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2666566165","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666566165?lang=en_us&edition=fundamental","pubTime":"2026-09-10 16:30","pubTimestamp":1789029000,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. slipped 3.6% to 8.77 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.3% to 24954.47.This was the stock's fourth consecutive day of losses.CSPC Pharmaceutical Group Ltd. closed 20% short of its 52-week high of HK$10.96, which the company reached Jan. 30.The stock demonstrated a mixed performance when compared to some of its competitors, as Sino Biopharmaceutical Ltd. fell 2.3%, SSY Group Ltd. fell 0.2%, and United Laboratories International Holdings Ltd. fell 3.9%.Trading volume totaled 150.3 million shares, compared to the 50-day average of 105.3 million shares.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","LU1226287792.SGD","IE00B031HY20.USD","LU0326950275.SGD","LU1226287529.USD","SG9999004220.SGD","LU1152091168.USD","LU1993786604.SGD","LU1960683339.HKD","LU0072913022.USD","IE0008368742.USD","IE00B5MMRT66.SGD","IE0008369823.USD","IE00B543WZ88.USD","LU1951186391.HKD","IE00BZ08YR35.GBP","LU2039709279.SGD","LU1152091754.HKD","LU1807302812.USD","LU1226288170.HKD","LU1008478684.HKD","LU0314109678.HKD","BK1521","01093","LU1328277881.USD","LU0880133367.SGD","IE00BZ08YS42.EUR","BK1515","LU0501845795.SGD","LU0067412154.USD","LU1813983027.USD","KURE","LU0315179316.USD","LU1226287875.USD","LU1226288253.USD","LU0140636845.USD","HK0000165453.HKD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666991563","title":"Global Equities Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2666991563","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666991563?lang=en_us&edition=fundamental","pubTime":"2026-09-10 15:22","pubTimestamp":1789024920,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering Equities. Published exclusively on Dow Jones Newswires throughout the day.0722 GMT - China Overseas Land & Investment could benefit from accelerating market consolidat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1316543674.SGD","LU0314109678.HKD","IE00BZ08YT58.USD","LU0140636845.USD","IE00BVYPNQ40.USD","LU1497733557.USD","LU1951186391.HKD","SG9999003800.SGD","LU0823413660.USD","LU0886674414.USD","LU2039709279.SGD","LU0072913022.USD","LU1211504680.USD","LU2257852520.SGD","SG9999008742.SGD","UN","LU1282649067.USD","LU0950375773.USD","LU0823397103.USD","LU1522347837.USD","SG9999004220.SGD","LU0577902454.USD","LU1152091168.USD","SG9999016042.SGD","03121","SG9999002604.SGD","LU1226288170.HKD","SG9999013460.SGD","LU1152091754.HKD","SG9999003925.USD","IE00BKZH1Z71.USD","LU0650527681.SGD","LU0856984785.SGD","LU1226287875.USD","LU0205439572.USD","LU0043850808.USD","IE00BZ08YS42.EUR","LU0865486749.SGD","LU2506952097.USD","SG9999007991.SGD","LU0737861269.HKD","SG9999001226.SGD","LU0384037296.USD","LU0084288322.USD","SG9999002620.SGD","LU0955623706.USD","SG9999010052.SGD","LU0011963245.USD","SGXZ43160589.SGD","LU0251143029.SGD","LU0557290698.USD","LU0588545904.SGD","BK4588","BK6516","LU1497733631.SGD","LU1328615791.USD","SG9999004360.SGD","LU0630378692.HKD","00688","LU1226288253.USD","LU0880133367.SGD","LU0955648018.USD","LU0648948544.HKD","BK4592","LU0882747503.HKD","SG9999005177.SGD","LU1993786604.SGD","SG9999003826.SGD","LU0971096721.USD","LU0823413587.USD","LU0577902611.USD","LU0823039010.USD","IE00BGHQDM52.EUR","LU0197773673.USD","LU2506951958.HKD","LU0048573645.USD","LU0873338254.USD","LU0543330483.HKD","LU0689626769.HKD","LU1130305938.SGD","LU1956131251.USD","LU0577902538.SGD","SGXZ58947870.SGD","LU0329678170.USD","LU0823417737.USD","LU1807302812.USD","LU0441854154.USD","SG9999013478.USD","IE00B543WZ88.USD","LU0532188223.SGD","BK1521","SG9999001903.USD","LU0577902371.SGD","01093","LU2506951875.HKD","LU1328277881.USD","BK1258","SG9999000475.SGD","LU0287142896.SGD","CAOVY","LU0173614495.USD","LU1226287529.USD","LU2226123227.USD","LU0315179316.USD","SG9999001127.SGD","LU2237957811.SGD","SG9999009443.AUD","BK4585","LU0169518387.USD","SGXZ51708014.SGD","LU1224709979.USD","BK1229","LU1839390173.USD","LU0588545730.USD","SG9999014484.SGD","LU0345776255.USD","SGXZ27511609.SGD","LU0823417653.USD","LU0029875118.USD","SG9999013353.USD","SG9999001135.SGD","LU0124676726.USD","SGXZ24219693.SGD","LU1960683339.HKD","SGXZ91733576.SGD","BK1515","LU0488056044.USD","LU2238330802.EUR","SGXZ16066938.SGD","IE0008368742.USD","LU1504937902.USD","IE00BHRH8D16.HKD","SG9999001846.SGD","LU0675040207.SGD","IE0003895053.USD","LU0588545490.SGD","IE00BHRH8C09.USD","LU2152927971.USD","IE00B031HY20.USD","IE00B5MMRT66.SGD","LU0326950275.SGD","BK4183","LU2237957902.USD","LU1634259391.SGD","LU0878004406.USD","LU1497734951.SGD","LU0605514214.HKD","HK0000165453.HKD","BK6112","BK1555","SG9999006266.SGD","LU0048597586.USD","IE00BVYPNP33.GBP","LU1363072403.SGD","LU0096374516.USD","LU0261945553.USD","LU0211331839.USD","IE0031814969.USD","LU1008478684.HKD","SG9999002406.SGD","01997","LU0831103253.SGD","IE00BZ08YR35.GBP","LU0251144936.SGD","LU0819121731.USD","UL","SG9999010078.USD","LU0441851309.USD","SG9999014302.SGD","LU1282649141.HKD","SG9999002414.USD","LU0594300419.USD","LU0737861699.HKD","LU0823397285.USD","LU0823038988.USD","LU0229494975.USD","LU0261947096.USD","SG9999000343.SGD","LU0128522157.USD","LU0235996351.USD","LU0898667661.SGD","SG9999002679.SGD","IE0008369823.USD","BK1240","LU0594300179.USD","SG9999011175.SGD","ULVR.UK","LU3227948356.SGD","KURE","LU0819123356.HKD","SG9999002562.SGD","LU0326948709.USD","LU0577902298.EUR","SGXZ70427877.SGD","LU0630378429.USD","IE00BG0RBZ43.SGD","LU0192582467.USD","LU2506952170.USD","LU1813983027.USD","LU1770036033.HKD","SG9999009997.SGD","LU0831093199.SGD","D05.SI","LU0315178854.USD","LU0329678337.USD","LU0672654166.SGD","LU0955669360.SGD","LU0061477393.USD","LU1634259557.SGD","LU0320764755.SGD","BK1601","SG9999014492.USD","LU0762540952.USD","LU0878005551.USD","LU0501845795.SGD","SG9999013486.USD","LU0197773160.USD","LU0737861772.HKD","BK1534","LU1226287792.SGD","LU0210637038.USD","LU2226123490.SGD","SG9999000459.SGD","BK6523","LU0188438112.USD","LU0165289439.USD","LU0067412154.USD","BK1191","LU1282649810.SGD","LU0345775950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119404417","title":"Hong Kong Market Flash | CSPC Pharma Drops Over 4% as Lp(a) HORIZON Study Setback May Pressure Participants Including the Company","url":"https://stock-news.laohu8.com/highlight/detail?id=1119404417","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119404417?lang=en_us&edition=fundamental","pubTime":"2026-09-10 14:26","pubTimestamp":1789021579,"startTime":"0","endTime":"0","summary":"Shares of CSPC PHARMA (01093) fell more than 4%, and at the time of writing, they were down 2.69% to HK$8.855, with a turnover of HK$938 million. CLSA issued a research note stating that the latest...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287529.USD","LU1960683339.HKD","KCAI","LU0880133367.SGD","BK1515","IE00B5MMRT66.SGD","LU0140636845.USD","SG9999004220.SGD","IE00B031HY20.USD","LU1226288170.HKD","LU0314109678.HKD","LU1328277881.USD","VXUS","LU0067412154.USD","IE00BZ08YT58.USD","LU0326950275.SGD","LU0072913022.USD","BK1521","IE00BZ08YR35.GBP","BK1191","LU2039709279.SGD","LU1813983027.USD","LU1951186391.HKD","LU1226288253.USD","KURE","LU0315179316.USD","IE00B543WZ88.USD","LU1008478684.HKD","IE0008369823.USD","BK4585","LU1226287792.SGD","BK4588","LU1152091754.HKD","IE0008368742.USD","LU1226287875.USD","LU1807302812.USD","IE00BZ08YS42.EUR","LU1993786604.SGD","LU1152091168.USD","LU0501845795.SGD","01093","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666987550","title":"CSPC Pharma's Clinical Data Presentations Could be Near-Term Share Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2666987550","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666987550?lang=en_us&edition=fundamental","pubTime":"2026-09-10 14:08","pubTimestamp":1789020480,"startTime":"0","endTime":"0","summary":"0608 GMT - CSPC Pharmaceutical's coming clinical data presentations over the next two months could serve as near-term share-price catalysts, say DBS Group Research's Mark Kong and Nico Chen in a note. The Chinese pharmaceutical group is scheduled to present on several key products, including Phase 3 clinical data for its GLP-1 fusion protein to treat obesity and diabetes, the analysts say. The company's voluntary participation is seen as a sign of confidence in the data, the analysts say. CSPC trades around 18X its 2027 price-to-earnings ratio, which is a roughly 28% discount to the peer average and offers an attractive entry point, they say. DBS reinstates its coverage of CSPC with a buy rating and 13.70 Hong Kong dollar target price. Shares fall 4.2% to HK$8.72.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0315179316.USD","LU1226287529.USD","LU0326950275.SGD","LU0501845795.SGD","IE0008368742.USD","LU0880133367.SGD","IE00B031HY20.USD","LU0314109678.HKD","LU1328277881.USD","LU1813983027.USD","LU0067412154.USD","IE00BZ08YS42.EUR","LU0072913022.USD","LU1226288253.USD","LU1008478684.HKD","LU1951186391.HKD","IE00B543WZ88.USD","HK0000165453.HKD","BK1515","LU1226287792.SGD","IE00BZ08YR35.GBP","LU0140636845.USD","LU2039709279.SGD","LU1226287875.USD","SG9999004220.SGD","IE0008369823.USD","01093","LU1226288170.HKD","LU1807302812.USD","LU1152091168.USD","LU1960683339.HKD","BK1191","LU1993786604.SGD","KURE","IE00BZ08YT58.USD","BK1521","LU1152091754.HKD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666536873","title":"WuXi Biologics Files HKEX Next-Day Disclosure, Share Capital Rises by 1.2 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2666536873","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666536873?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:38","pubTimestamp":1788961137,"startTime":"0","endTime":"0","summary":"WuXi Biologics files HKEX next-day disclosure, share capital rises by 1.2 million sharesWuXi Biologics filed a next-day disclosure return on Sept. 9, 2026, reporting 1,200,000 new ordinary shares issu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL3Fk8Yw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201612.USD","LU0516422952.EUR","LU2039709279.SGD","LU0516423174.USD","LU0456827905.SGD","LU0588546209.SGD","BK1589","BK1141","LU0979878070.USD","LU1720050803.USD","SG9999002562.SGD","IE00B0JY6N72.USD","LU0348735423.USD","BK1576","LU0140636845.USD","LU0051755006.USD","LU0417516902.SGD","LU0359202008.SGD","02269","BK1610","LU0307460666.USD","LU0029874061.USD","LU0516422440.USD","LU0516422366.SGD","LU1688375341.USD","LU0128526141.USD","LU1794554557.SGD","LU0320764599.SGD","LU0708995583.HKD","LU0456846285.SGD","LU0823426308.USD","LU0326950275.SGD","LU0572944931.SGD","LU0856984785.SGD","LU1880383366.USD","LU1242518857.USD","LU0819121731.USD","SG9999002463.SGD","LU0181495838.USD","LU0417516738.SGD","LU0348825331.USD","KURE","LU0516423091.SGD","LU0327786744.USD","LU0039217434.USD","LU0043850808.USD","LU1242518931.SGD","LU3063872942.SGD","LU0823426480.USD","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538664","title":"Transcenta Licenses HiCB Bioprocessing Technology to WuXi Biologics for RMB 10 Million Upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538664","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538664?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:03","pubTimestamp":1788955391,"startTime":"0","endTime":"0","summary":"Transcenta licenses HiCB bioprocessing technology to WuXi Biologics for RMB 10 million upfrontTranscenta entered a technology licensing and strategic collaboration agreement with WuXi Biologics coveri","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDLbxChqk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0181495838.USD","LU0039217434.USD","LU0417516738.SGD","SG9999006597.SGD","SG9999002562.SGD","SGXZ90724238.SGD","LU1242518857.USD","LU0307460666.USD","LU0140636845.USD","LU0417516902.SGD","LU0128526141.USD","LU0823397103.USD","LU0588546209.SGD","BK0196","LU2289578879.USD","IE00B0JY6N72.USD","BK1161","LU0823426308.USD","BK1521","KURE","LU2213484517.USD","02269","LU0823426480.USD","LU0052750758.USD","LU0456846285.SGD","LU1997244956.HKD","LU1997245177.USD","LU0516422366.SGD","LU2039709279.SGD","BK1141","LU0572944931.SGD","LU2148510915.USD","LU0029874061.USD","LU0823413660.USD","601939","BK0015","LU0051755006.USD","LU1064131003.USD","06628","BK0187","BK1610","LU1688375341.USD","LU0320764599.SGD","LU1064130708.USD","LU1880383366.USD","LU0043850808.USD","LU0516423091.SGD","SG9999001226.SGD","BK0183","LU0456827905.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538344","title":"Transcenta Holding - to Receive RMB 10 Mln Upfront Payment and Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538344","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538344?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:00","pubTimestamp":1788955210,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA8NNVMW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0327786744.USD","LU0359201612.USD","LU0326950275.SGD","LU1720050803.USD","02269","LU2039709279.SGD","LU1242518857.USD","LU0029874061.USD","LU1688375341.USD","LU0307460666.USD","06628","BK1161","LU0039217434.USD","BK1576","LU0128526141.USD","LU1794554557.SGD","LU0979878070.USD","BK1141","LU1880383366.USD","LU0140636845.USD","LU0588546209.SGD","LU0181495838.USD","LU0516422440.USD","BK1589","LU1242518931.SGD","LU0348825331.USD","LU0348735423.USD","BK1610","LU0516422366.SGD","LU0320764599.SGD","LU0456846285.SGD","BK1521","LU0516423091.SGD","LU0359202008.SGD","LU0516423174.USD","LU0856984785.SGD","LU0052750758.USD","LU0708995583.HKD","LU0819121731.USD","LU0456827905.SGD","KURE","SG9999002463.SGD","SG9999002562.SGD","LU0417516902.SGD","LU0823426480.USD","IE00B0JY6N72.USD","LU0043850808.USD","LU0051755006.USD","LU0516422952.EUR","LU0823426308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666383175","title":"Transcenta Holding - Grants WuXi Biologics Non-Exclusive License to Hicb Platform and Excelpro Cell Culture Media","url":"https://stock-news.laohu8.com/highlight/detail?id=2666383175","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666383175?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:00","pubTimestamp":1788955210,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA8NNVMW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1880383366.USD","LU1720050803.USD","LU0516423091.SGD","LU0516423174.USD","LU0572944931.SGD","LU0708995583.HKD","LU0326950275.SGD","LU1794554557.SGD","LU1242518931.SGD","LU0043850808.USD","IE00B0JY6N72.USD","LU0140636845.USD","LU0359202008.SGD","LU0456846285.SGD","LU0348825331.USD","LU0320764599.SGD","LU0823426308.USD","BK1521","LU0128526141.USD","BK1589","LU0181495838.USD","LU0348735423.USD","LU0516422366.SGD","LU0516422952.EUR","LU3063872942.SGD","BK1610","LU0307460666.USD","SG9999002562.SGD","LU0823426480.USD","BK1576","LU0588546209.SGD","LU0856984785.SGD","LU0979878070.USD","LU1688375341.USD","LU0359201612.USD","02269","LU0417516738.SGD","LU0819121731.USD","LU0052750758.USD","06628","LU0051755006.USD","KURE","LU0516422440.USD","LU2039709279.SGD","LU0456827905.SGD","LU0327786744.USD","LU0029874061.USD","LU0417516902.SGD","LU0039217434.USD","LU1242518857.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587876","title":"CSPC Pharma Gets Clinical Trial Nod in China for Solid Tumors Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587876","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587876?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951640,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group's (HKG:1093) SYH9102 injection obtained clinical trial approval from China's National Medical Products Administration.The clinical indication is for patients with solid tumors, according to a Wednesday Hong Kong bourse filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0067412154.USD","BK1191","LU1993786604.SGD","01093","IE00B543WZ88.USD","LU0315179316.USD","LU0314109678.HKD","LU0140636845.USD","LU1226287792.SGD","SG9999004220.SGD","BK1521","LU1951186391.HKD","LU1152091168.USD","IE00BZ08YT58.USD","LU1008478684.HKD","LU0072913022.USD","LU0326950275.SGD","LU1152091754.HKD","IE00B5MMRT66.SGD","LU2039709279.SGD","HK0000165453.HKD","LU1226288170.HKD","LU1226287875.USD","LU0501845795.SGD","BK1515","KURE","LU1226288253.USD","LU0880133367.SGD","LU1328277881.USD","LU1807302812.USD","IE0008368742.USD","LU1813983027.USD","IE0008369823.USD","LU1960683339.HKD","LU1226287529.USD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666828235","title":"CSPC Pharmaceutical Says Rotigotine Long-Acting Injection Gets Clinical Trial Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2666828235","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666828235?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:34","pubTimestamp":1788950057,"startTime":"0","endTime":"0","summary":"BRIEF-CSPC Pharmaceutical Says Rotigotine Long-Acting Injection Gets Clinical Trial Approval In ChinaSept 9 (Reuters)-CSPC PHARMACEUTICAL GROUP LIMITED1093.HK:ROTIGOTINE LONG-ACTING INJECTION (SYH9087 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINAFurther company coverage:1093.HK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN45104B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","LU0501845795.SGD","LU1226288170.HKD","IE00BZ08YT58.USD","LU0072913022.USD","SG9999004220.SGD","LU1152091754.HKD","LU1328277881.USD","LU1993786604.SGD","LU2039709279.SGD","LU1008478684.HKD","IE00B543WZ88.USD","IE00BZ08YR35.GBP","LU1960683339.HKD","LU0880133367.SGD","01093","LU1813983027.USD","LU1152091168.USD","BK1521","IE00B031HY20.USD","LU0314109678.HKD","BK1191","BK1515","LU0315179316.USD","LU1226288253.USD","IE0008368742.USD","HK0000165453.HKD","IE00BZ08YS42.EUR","LU1951186391.HKD","LU0067412154.USD","LU1226287529.USD","LU1226287875.USD","LU0140636845.USD","IE00B5MMRT66.SGD","LU1226287792.SGD","LU1807302812.USD","KURE","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151768833","title":"CSPC Pharma's Goserelin Extended-Release Injection Gets Clinical Trial Green Light in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1151768833","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151768833?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:12","pubTimestamp":1788948739,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has announced that its self-developed gonadotropin-releasing hormone (GnRH) receptor agonist, Goserelin Extended-Release Injection (SYH9102 Injection), has received approval from...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1813983027.USD","LU1152091168.USD","LU1951186391.HKD","LU2039709279.SGD","LU0314109678.HKD","IBBQ","IE00B5MMRT66.SGD","LU1993786604.SGD","IBBJ","LU1226288253.USD","HK0000165453.HKD","LU1960683339.HKD","LU0067412154.USD","IE00B031HY20.USD","LU1226287875.USD","LU0880133367.SGD","LU0072913022.USD","IE00BZ08YS42.EUR","LU1226288170.HKD","MDTX","LU0140636845.USD","BK1191","LU1328277881.USD","BK1521","LU1152091754.HKD","LU0315179316.USD","LU0501845795.SGD","BK1515","BMED","IE00BZ08YR35.GBP","LU1226287792.SGD","SG9999004220.SGD","LU1807302812.USD","PSYK","IE00B543WZ88.USD","IE0008368742.USD","LU0326950275.SGD","01093","LU1226287529.USD","LU1008478684.HKD","KURE","IE00BZ08YT58.USD","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100647125","title":"CSPC Pharma Gains Chinese Clinical Trial Approval for Goserelin Extended-Release Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1100647125","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100647125?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:12","pubTimestamp":1788948739,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has announced that its self-developed gonadotropin-releasing hormone (GnRH) receptor agonist, Goserelin Extended-Release Injection (SYH9102 Injection), has received approval from...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0067412154.USD","LU0314109678.HKD","LU1813983027.USD","LU1951186391.HKD","LU1993786604.SGD","LU1226288253.USD","LU1226287792.SGD","IE00BZ08YT58.USD","LU0140636845.USD","IE0008369823.USD","BK1521","LU1226288170.HKD","LU0315179316.USD","LU1152091168.USD","HK0000165453.HKD","LU1328277881.USD","IE00B031HY20.USD","LU1008478684.HKD","BMED","LU1226287529.USD","LU1152091754.HKD","LU1226287875.USD","LU1960683339.HKD","IE00B543WZ88.USD","IE00BZ08YR35.GBP","01093","IBBQ","LU1807302812.USD","LU0501845795.SGD","BK1191","KURE","SG9999004220.SGD","LU2039709279.SGD","LU0880133367.SGD","IE0008368742.USD","LU0326950275.SGD","MDTX","IE00B5MMRT66.SGD","LU0072913022.USD","BK1515","PSYK","IE00BZ08YS42.EUR","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666610584","title":"CSPC Pharma Wins China Clinical Trial Clearance for Syh9102 Goserelin Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2666610584","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666610584?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:11","pubTimestamp":1788948662,"startTime":"0","endTime":"0","summary":"CSPC Pharma wins China clinical trial clearance for SYH9102 goserelin injectionCSPC Pharmaceutical Group received China NMPA clearance to start clinical trials of its goserelin sustained-release injec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL9BYJhM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226288253.USD","LU1993786604.SGD","LU1152091754.HKD","LU0140636845.USD","LU1152091168.USD","LU1951186391.HKD","IE00B543WZ88.USD","LU1226287792.SGD","BK1515","IE00BZ08YR35.GBP","LU1226288170.HKD","LU0880133367.SGD","LU1807302812.USD","LU0067412154.USD","BK1191","IE00B5MMRT66.SGD","LU0314109678.HKD","LU1328277881.USD","LU1960683339.HKD","LU1226287875.USD","IE0008368742.USD","LU0501845795.SGD","01093","IE00B031HY20.USD","LU2039709279.SGD","SG9999004220.SGD","LU0315179316.USD","BK1521","HK0000165453.HKD","KURE","LU1008478684.HKD","LU1226287529.USD","LU0326950275.SGD","LU1813983027.USD","IE00BZ08YT58.USD","LU0072913022.USD","IE00BZ08YS42.EUR","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584556","title":"CSPC Pharmaceutical - Goserelin Sustained-Release Injection (Syh9102 Injection) Obtains Clinical Trial Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584556?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:07","pubTimestamp":1788948434,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN450126:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0072913022.USD","IE00B031HY20.USD","HK0000165453.HKD","IE00BZ08YR35.GBP","LU0314109678.HKD","IE00B543WZ88.USD","LU1813983027.USD","LU1960683339.HKD","IE00BZ08YT58.USD","IE0008369823.USD","LU1993786604.SGD","LU0140636845.USD","LU1807302812.USD","IE00B5MMRT66.SGD","LU1226287875.USD","LU2039709279.SGD","LU0880133367.SGD","SG9999004220.SGD","01093","LU1152091754.HKD","LU1226287792.SGD","LU0315179316.USD","LU1328277881.USD","BK1191","BK1515","IE0008368742.USD","LU1226288253.USD","LU1951186391.HKD","LU1226288170.HKD","LU1226287529.USD","LU1008478684.HKD","LU0326950275.SGD","LU0501845795.SGD","LU0067412154.USD","KURE","IE00BZ08YS42.EUR","LU1152091168.USD","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191216573","title":"CLSA Highlights Return of Stock-Specific Drivers in China's Innovative Drug Sector, Sees Macro Swings as Entry Points","url":"https://stock-news.laohu8.com/highlight/detail?id=1191216573","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191216573?lang=en_us&edition=fundamental","pubTime":"2026-09-09 14:06","pubTimestamp":1788933977,"startTime":"0","endTime":"0","summary":"China's innovative drug sector is swinging back to a market led by company fundamentals and stock-specific alpha, according to a research note from CLSA. The influence of particular company...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03692","KURE","BK1589","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665214203","title":"CSPC Pharmaceutical Gets China Approval for Eye Drug Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2665214203","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665214203?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:13","pubTimestamp":1788862439,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group's (HKG:1093) SYH2083 eye drops received approval from the National Medical Products Administration to begin clinical trials in China.The class 1 innovative drug is being developed for dry eye disease, according to a Tuesday Hong Kong bourse filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0067412154.USD","LU0072913022.USD","LU0326950275.SGD","LU2039709279.SGD","LU0501845795.SGD","LU1008478684.HKD","LU1152091168.USD","IE00BZ08YS42.EUR","LU1152091754.HKD","IE00BZ08YT58.USD","LU1813983027.USD","01093","IE00B5MMRT66.SGD","LU0315179316.USD","KURE","IE0008368742.USD","BK1521","HK0000165453.HKD","BK1191","IE0008369823.USD","LU1226288253.USD","IE00BZ08YR35.GBP","SG9999004220.SGD","LU0880133367.SGD","BK1515","LU1226288170.HKD","LU1993786604.SGD","LU0314109678.HKD","LU1328277881.USD","LU1951186391.HKD","LU1226287875.USD","IE00B543WZ88.USD","LU1807302812.USD","LU1960683339.HKD","LU0140636845.USD","IE00B031HY20.USD","LU1226287529.USD","LU1226287792.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329613","title":"CSPC Wins China Clinical Trial Approval for Syh2083 Dry Eye Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329613","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329613?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:47","pubTimestamp":1788860844,"startTime":"0","endTime":"0","summary":"CSPC wins China clinical trial approval for SYH2083 dry eye dropsCSPC received China NMPA clearance to start clinical trials of SYH2083 eye drops, a small-molecule novel drug.Initial indication target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL4D1fT5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","LU0314109678.HKD","LU1813983027.USD","IE00B543WZ88.USD","LU1152091754.HKD","LU1152091168.USD","LU0067412154.USD","KURE","BK1515","LU0501845795.SGD","01093","LU1328277881.USD","LU0880133367.SGD","IE00BZ08YS42.EUR","SG9999004220.SGD","IE0008369823.USD","BK1191","IE00B5MMRT66.SGD","LU1807302812.USD","LU1960683339.HKD","LU0326950275.SGD","LU1226287529.USD","LU1993786604.SGD","LU1226288253.USD","LU1008478684.HKD","HK0000165453.HKD","BK1521","IE00B031HY20.USD","LU1226287875.USD","IE0008368742.USD","IE00BZ08YR35.GBP","LU1951186391.HKD","LU0072913022.USD","LU2039709279.SGD","LU0315179316.USD","LU1226287792.SGD","LU0140636845.USD","LU1226288170.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329660","title":"CSPC Pharmaceutical - Syh2083 Eye Drops Obtain Clinical Trial Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329660","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329660?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:47","pubTimestamp":1788860822,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN44Z0GM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B5MMRT66.SGD","LU0501845795.SGD","LU0326950275.SGD","LU1226287875.USD","HK0000165453.HKD","IE00BZ08YT58.USD","IE0008369823.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","01093","LU0140636845.USD","LU0067412154.USD","BK1191","BK1515","LU1226288170.HKD","LU1226287792.SGD","LU2039709279.SGD","LU1152091168.USD","LU1951186391.HKD","LU1226288253.USD","KURE","LU1328277881.USD","LU0880133367.SGD","LU1813983027.USD","LU1960683339.HKD","IE0008368742.USD","SG9999004220.SGD","LU1993786604.SGD","IE00B543WZ88.USD","LU0315179316.USD","IE00B031HY20.USD","LU1226287529.USD","LU1008478684.HKD","LU1807302812.USD","LU0314109678.HKD","LU0072913022.USD","BK1521","LU1152091754.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}